Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Compliance with Pregnancy Prevention Recommendations for Isotretinoin in Estonia in 2012–2016

Compliance with Pregnancy Prevention Recommendations for Isotretinoin in Estonia in 2012–2016 Drugs - Real World Outcomes (2018) 5:129–136 https://doi.org/10.1007/s40801-018-0135-z OR IGINAL RESEARCH ARTIC L E Compliance with Pregnancy Prevention Recommendations for Isotretinoin in Estonia in 2012–2016 1 1 2 2 3 • • • • • Anneli Uusku ¨ la Heti Pisarev Katrin Kurvits Ott Laius Made Laanpere Maia Uusku ¨ la Published online: 22 May 2018 The Author(s) 2018 Abstract The odds for full coverage with effective contraception Background Isotretinoin is an effective treatment for sev- increased with the age of the patient, with the duration of ere acne; no alternative treatment has an equal therapeutic isotretinoin treatment and over the period of observation. effect. The teratogenic effects of isotretinoin can be avoi- Conclusion Our study adds to the existing literature doc- ded, and numerous recommendations and regulations are in umenting limited compliance with pregnancy prevention force to minimize the risk of pregnancy during treatment. programs for isotretinoin-containing products, and calls for Objectives To describe isotretinoin prescription patterns program assessment to identify whether new measures for women aged 15–45 years, assess the concomitancy of should be taken or whether weaknesses in policy or isotretinoin and contraceptive use, and determine the rate implementation can be corrected. of potential isotretinoin-exposed pregnancies http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Drugs - Real World Outcomes Springer Journals

Compliance with Pregnancy Prevention Recommendations for Isotretinoin in Estonia in 2012–2016

Download PDF
8 pages

Loading next page...
 
/lp/springer_journal/compliance-with-pregnancy-prevention-recommendations-for-isotretinoin-LpU0UqULYG
Publisher
Springer Journals
Copyright
Copyright © 2018 by The Author(s)
Subject
Medicine & Public Health; Pharmacotherapy; Pharmacology/Toxicology; Internal Medicine
ISSN
2199-1154
eISSN
2198-9788
DOI
10.1007/s40801-018-0135-z
Publisher site
See Article on Publisher Site

Abstract

Drugs - Real World Outcomes (2018) 5:129–136 https://doi.org/10.1007/s40801-018-0135-z OR IGINAL RESEARCH ARTIC L E Compliance with Pregnancy Prevention Recommendations for Isotretinoin in Estonia in 2012–2016 1 1 2 2 3 • • • • • Anneli Uusku ¨ la Heti Pisarev Katrin Kurvits Ott Laius Made Laanpere Maia Uusku ¨ la Published online: 22 May 2018 The Author(s) 2018 Abstract The odds for full coverage with effective contraception Background Isotretinoin is an effective treatment for sev- increased with the age of the patient, with the duration of ere acne; no alternative treatment has an equal therapeutic isotretinoin treatment and over the period of observation. effect. The teratogenic effects of isotretinoin can be avoi- Conclusion Our study adds to the existing literature doc- ded, and numerous recommendations and regulations are in umenting limited compliance with pregnancy prevention force to minimize the risk of pregnancy during treatment. programs for isotretinoin-containing products, and calls for Objectives To describe isotretinoin prescription patterns program assessment to identify whether new measures for women aged 15–45 years, assess the concomitancy of should be taken or whether weaknesses in policy or isotretinoin and contraceptive use, and determine the rate implementation can be corrected. of potential isotretinoin-exposed pregnancies

Journal

Drugs - Real World Outcomes – Springer Journals

Published: May 22, 2018

References

  • Advice on the safe introduction and continued use of isotretinoin in acne in the U.K. 2010
    Goodfield, MJ; Cox, NH; Bowser, A
  • Implementation of the harmonized EU isotretinoin Pregnancy Prevention Programme: a questionnaire survey among European regulatory agencies
    Crijns, I; Straus, S; Luteijn, M
  • Compliance with pregnancy prevention programmes of isotretinoin in Europe: a systematic review
    Crijns, HJ; Straus, SM; Gispen-de Wied, C
  • Concomitant use of isotretinoin and contraceptives before and after iPledge in the United States
    Pinheiro, SP; Kang, EM; Kim, CY
  • Isotretinoin use and compliance with the Dutch Pregnancy Prevention programme: a retrospective cohort study in females of reproductive age using pharmacy dispensing data
    Teichert, M; Visser, LE; Dufour, M
  • Occurrence of pregnancy and pregnancy outcomes during isotretinoin therapy
    Henry, D; Dormuth, C; Winquist, B
  • The impact of the iPLEDGE program on isotretinoin fetal exposure in an integrated health care system
    Shin, J; Cheetham, TC; Wong, L
  • A pregnancy-prevention program in women of childbearing age receiving isotretinoin
    Mitchell, AA; Bennekom, CM; Louik, C
  • Trends in adherence to a revised risk management program designed to decrease or eliminate isotretinoin-exposed pregnancies: evaluation of the accutane SMART program
    Brinker, A; Kornegay, C; Nourjah, P
  • We pledge to change iPLEDGE
    Pierson, JC; Ferris, LK; Schwarz, EB
  • Oral isotretinoin and pregnancy prevention programmes
    Thiboutot, D; Gollnick, H; Bettoli, V
  • Isotretinoin exposure during pregnancy: a population-based study in The Netherlands
    Zomerdijk, IM; Ruiter, R; Houweling, LM